MelasQoL (Melasma Quality of Life Scale)
Melasma Quality of Life Scale · Also known as: Melasma-QoL
MelasQoL is a disease-specific, patient-administered quality-of-life measure designed to assess the psychosocial burden of melasma, a common chronic disorder of symmetric facial hyperpigmentation. Developed by Cestari and colleagues in 2006, it captures the unique emotional and social impacts of a predominantly cosmetic condition that disproportionately affects women of color. MelasQoL is essential in clinical trials and observational studies of melasma treatments to ensure that efficacy encompasses meaningful quality-of-life outcomes.
Read the full method
Sign in with a free account to read this section.
Method map
The neighbourhood of related methods — select a node to explore.
When to use it
MelasQoL is indicated in all clinical and research settings focused on melasma care, particularly in trials of melasma treatments (topical depigmenting agents, laser/light therapies, combination therapies). It should be assessed at baseline, 8–12 weeks, and final visit in clinical trials. In routine clinical practice, periodic assessment (every 3–6 months during treatment) identifies patients experiencing high psychological burden and guides psychological support or therapy escalation. MelasQoL is particularly valuable in diverse populations where melasma prevalence is high (Hispanic, Middle Eastern, East Asian, and African descent populations) and where appearance-related distress may be culturally amplified.
Strengths & limitations
- Disease-specific focus; items directly address melasma-relevant psychosocial impacts rather than generic dermatology outcomes.
- Patient-centered; captures what matters most to melasma patients: appearance satisfaction and emotional/social functioning.
- Brief and simple; 7 items, 0–4 Likert scale, completion in 3–5 minutes; very low respondent burden.
- Responsive to treatment; sensitive to clinically meaningful improvement with depigmenting and laser therapies.
- Culturally sensitive; validated in diverse populations with high melasma prevalence.
- Practical for routine clinical use and remote monitoring.
- Endorsed by dermatology societies specializing in pigmentary disorders.
- Limited psychometric data compared to generic QoL measures; fewer validation studies in diverse populations.
- No established severity thresholds or cutoff scores; interpretation relies on change-from-baseline or comparison to controls.
- Subjective recall; patients' memory of QoL impact over the past month may be influenced by recent treatment experiences or mood.
- Does not capture objective disease severity (MASI, extent, color); purely patient-perceived impact.
- May reflect broader body image or mental health issues beyond melasma; patients with comorbid depression/anxiety may have high MelasQoL independent of melasma severity.
- Limited data on minimal clinically important difference (MCID); recommended ≥3 points is expert consensus, not empirically derived.
- Available in fewer languages than generic instruments (DLQI, Skindex).
Frequently asked
How does melasma QoL burden compare to other dermatological conditions?
Melasma patients often report quality-of-life impacts comparable to or exceeding those of patients with more objectively 'severe' conditions like psoriasis or atopic dermatitis. This is because melasma is highly visible, affects the face (identity-salient region), and occurs disproportionately in populations where it may carry cultural or ethnic significance. A high MelasQoL score should be taken seriously despite mild clinical severity.
What is the MCID for MelasQoL?
The minimal clinically important difference (MCID) for MelasQoL is estimated at ≥3 points (out of 28), based on expert consensus and preliminary studies. However, empirical derivation of MCID is limited. A 50% reduction in baseline MelasQoL (MelasQoL-50 response) is also used in some trials as an efficacy threshold.
Should MelasQoL be combined with objective severity measures like MASI?
Yes. MASI (Melasma Area and Severity Index) measures objective extent and color uniformity; MelasQoL measures subjective QoL impact. They do not correlate perfectly. Use both in trials and clinical monitoring for comprehensive assessment of treatment efficacy.
Is MelasQoL suitable for male patients with melasma?
Although melasma predominantly affects women, it does occur in men (10–20% of cases). MelasQoL has been validated in mixed-gender cohorts and is appropriate for use in men. However, gender-specific item responses and cultural attitudes toward cosmetic concerns may vary; always assess individual context and avoid gender-based assumptions.
How should I counsel a patient with high MelasQoL but mild clinical severity?
High MelasQoL with mild clinical severity indicates significant emotional burden disproportionate to objective disease. Validate the patient's concerns; melasma-related distress is real and warranted. Consider concurrent psychological support (counseling, cognitive-behavioral therapy) alongside dermatological treatment. Assess for body dysmorphic features, social anxiety, or depression; if present, mental health intervention may be as important as dermatological therapy.
Sources
- Cestari TF, Hexsel D, Brandt FS, et al. Validation of a melasma quality of life questionnaire for Brazilian Portuguese language: the MelasQoL. Br J Dermatol. 2006;156(Suppl 3):13-20. link ↗
- Pandya AG, Hynan LS, Bhore R, et al. Reliability and validity of the Melasma Area and Severity Index (MASI) and a new modified MASI scoring method. J Am Acad Dermatol. 2011;64(1):78-83. link ↗
How to cite this page
ScholarGate. (2026, June 3). Melasma Quality of Life Scale. ScholarGate. https://scholargate.app/en/dermatology/melasqol
Which method?
Set this method beside its closest kin and read them side by side — the library lays the books on the table; the choice is yours.
- Children's DLQIDermatology↔ compare
- POEMDermatology↔ compare
- Skindex-29Dermatology↔ compare